ArticleThe Pan African medical journal2025
Article in The Pan African medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The 2022 global mpox outbreak highlighted the critical importance of public health emergency preparedness. Although mpox is not a new disease, its sudden emergence and rapid spread in many countries, including Cameroon, raised numerous concerns about the ability of health systems to respond effectively. This study aimed to assess the level of preparedness of health districts in the Littoral Region of Cameroon in the event of a potential mpox outbreak, to identify strengths, weaknesses, and priority areas for intervention. We conducted a descriptive cross-sectional study in the health districts of the Littoral Region of Cameroon from August to September 2024. A grid for evaluating preparedness for a potential mpox outbreak was developed and administered to the district health management teams. This tool was based on the Integrated Disease Surveillance and Response (IDSR) technical guidelines. Data collected were analyzed using Microsoft Excel 2016. A total of 17 health districts were surveyed. Regarding their level of preparedness, 5 districts (29%) showed insufficient preparedness (Nkondjock, Loum, Manoka, Ndom, Pouma); 3 districts (17%) had limited preparedness (Boko, Manjo, Dibombari); 7 districts (41%) had an average level of preparedness (Bangue, Edea, Logbaba, Ngambe, Yabassi, Njombe Penja, Nkongsamba); and only 2 districts (11%) demonstrated good preparedness (Newbell, Mbanga). No district in the region reached the optimal level of preparedness. Significant disparities were observed among the districts, with preparedness scores ranging from 0.16 (Nkondjock) to 3.21 (Newbell). Epidemiological surveillance and laboratory capacity had the highest preparedness level (average preparedness score of 3.01), in contrast to case management (insufficient preparedness score of 1.07). The main barriers to preparedness included the absence of a specific mpox response plan, inadequate allocation of financial and material resources, insufficient diagnostic and laboratory confirmation capacity, lack of clinical management protocols, limited training of health personnel on case management, and absence of a risk communication plan. The health districts in the Littoral Region of Cameroon generally exhibited a limited level of preparedness. Several obstacles to preparedness were identified. To prevent a potential mpox outbreak, it is essential to strengthen district-level preparedness, particularly in coordination and response management, case management, risk communication and community engagement, and prevention and control measures, while adopting a differentiated approach that accounts for disparities between districts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.